The 2 biomarkers, SGK1 and ENPP1, and 2 chemical compounds, Stepholidine and Adenosine triphosphate, were first discovered playing a potential role in the treatment of BPH. The gene discussed is SGK1; the disease is benign prostatic hyperplasia.